Payment overview · 2025
General Payments
$490.20
19 reported records · 8 companies
Healthcare provider profile · identity verified
Steven J Stanton
Podiatric Medicine & Surgery Service Providers|Podiatrist · CYPRESS, TX · NPI 1043214919
Verified facts
What the public records show
CMS Open Payments records show Steven J Stanton received $490.20 in general payments during 2025 across 19 reported records.
Paratek Pharmaceuticals, Inc. accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jublia.
Ortho Dermatologics, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JUBLIA as an associated drug or biological on 5397 records involving 2963 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jublia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $135.61 | 27.7% | 8 | 2025 |
| Bone Support Inc. | Unresolved — no canonical attribution shown | $120.62 | 24.6% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $91.47 | 18.7% | 3 | 2025 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.81 | 7.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.70 | 6.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.32 | 6.0% | 2 | 2025 |
| Medimetriks Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.67 | 4.8% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $22.00 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $450.25 | 18 |
| Education | $39.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $135.61 | 8 | 2025 |
Source payment records
|
|||||
| CERAMENT G Normalized: cerament g |
Device | Bone Support Inc. | $120.62 | 1 | 2025 |
Source payment records
|
|||||
| CERAMENTBONE VOID FILLER Normalized: ceramentbone void filler |
Device | Bone Support Inc. | $120.62 | 1 | 2025 |
Source payment records
|
|||||
| JUBLIA Normalized: jublia |
Drug | Ortho Dermatologics, a division of Bausch Health US, LLC | $34.81 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $32.70 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $29.32 | 2 | 2025 |
Source payment records
|
|||||
| Clindacin ETZ Normalized: clindacin etz |
Medical Supply | Medimetriks Pharmaceuticals, Inc. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| Genadur Normalized: genadur |
Drug | Medimetriks Pharmaceuticals, Inc. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| Neo-Synalar Normalized: neo synalar |
Drug | Medimetriks Pharmaceuticals, Inc. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JUBLIA jublia |
2025 | Jublia | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Ortho Dermatologics, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | JUBLIA open payments reported associated product |
CMS Open Payments — General Payments 5397 supporting records · 2963 recipient NPIs · example record 1220077864 |
Jublia · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ciclopirox | Ciclopirox Olamine | 185 | 75 |
| Ammonium Lactate | Ammonium Lactate | 127 | 68 |
| Mupirocin | Mupirocin | 116 | 67 |
| Gabapentin | Gabapentin | 64 | 24 |
| Methylprednisolone | Methylprednisolone | 48 | 37 |
| Ciclopirox | Ciclopirox | 45 | 29 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 21 |
| Meloxicam | Meloxicam | 34 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 19 |
| Jublia | Efinaconazole | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Imiquimod | Imiquimod | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $490.20 · 19 records | Paratek Pharmaceuticals, Inc. | CERAMENT G, CERAMENTBONE VOID FILLER, Clindacin ETZ, Genadur, JUBLIA, KRYSTEXXA, NUZYRA, Neo-Synalar, PURIFIED CORTROPHIN GEL, QUTENZA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jublia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Ortho Dermatologics, a division of Bausch Health US, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error